A history of investigation on the mood stabilizing effect of carbamazepine in Japan

  title={A history of investigation on the mood stabilizing effect of carbamazepine in Japan},
  author={Teruo Ōkuma and Akira Kishimoto},
  journal={Psychiatry and Clinical Neurosciences},
  • T. ŌkumaA. Kishimoto
  • Published 1 February 1998
  • Psychology, Medicine
  • Psychiatry and Clinical Neurosciences
Abstract A history of investigation on the antimanic and prophylactic effects of carbamazepine in Japan is described. Following the initial open trials in the early 1970s in which the antimanic and prophylactic effects of carbamazepine were indicated for the first time in the world, the mood stabilizing effect was confirmed by the double blind studies which were performed with a multi‐institutional cooperation in Japan in the late 1970s. During the course of the double blind trials, the problem… 

Thirty Years of Clinical Experience with Carbamazepine in the Treatment of Bipolar Illness

Clinical and research experience with carbamazepine alone and in combination with lithium, valproic acid and other agents in complex combination treatment of bipolar illness is reviewed.

Carbamazepine extended-release capsules for the treatment of bipolar I disorder

The efficacy, safety, and tolerability of the extended-release capsule formulation of carbamazepine was demonstrated in two randomized, double-blind, placebo-controlled trials and an open-label extension study in patients with bipolar I disorder experiencing either manic or mixed episodes.

Carbamazepine extended-release capsules: a new treatment option for bipolar I disorder

  • R. Weisler
  • Psychology, Medicine
    Expert review of neurotherapeutics
  • 2005
The results of two large placebo-controlled, 3-week trials demonstrated that monotherapy with carbamazepine extended-release capsules was effective for the treatment of acute mania in patients with bipolar I disorder.

Mood stabilizers for patients with bipolar disorder: the state of the art

An updated review of the available literature in relation to the role of mood stabilizers in bipolar disorder, with particular emphasis on their mechanism of action, main clinical aspects and specific use in the different phases of BD treatment, according to the most recently published international treatment guidelines.

Tratamento farmacológico do transtorno bipolar: as evidências de ensaios clínicos randomizados Pharmacological Treatment of Bipolar Disorder: Evidence from Randomized Clinical Trials

The present article is a synthesis of the published clinical trials about the treatment of Bipolar disorder (BD). The methodology used to search the literature is described and results are presented.

Effect of Carbamazepine on the serum level of Thyrotropin Releasing Hormone

  • U. KalsoomN. Ali
  • Medicine, Biology
    International Journal of Basic & Clinical Pharmacology
  • 2019
The data suggest that Carbamazepine monotherapy does alter thyroid hormones and its central regulatory hormone TRH, which could have very important clinical implications.

Calcium Channel Antagonists for Mood Disorders.

The use of novel medications that act on this mechanism of neuronal activation as potential mood stabilizers that antagonize hyperactive intracellular signaling warrant more interest than they have received in psychiatry.



Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study

Improvements in basic mood, insomnia, headache and lassitude, and diurnal fluctuations of mood tended to be characteristic of carbamazepine efficacy for mania compared with the effects of chlorpromazine.

Use of Carbamazepine in Acute Psychosis: A Controlled Study

Results confirm that CBZ is a valid alternative to lithium in the treatment of acute psychosis and no clinically relevant differences were found between the two groups.

Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study.

While the shortcomings of the present study limit the interpretation of the data, it may be suggested that the usefulness of CBZ as a drug for the treatment of manic states is comparable to that of Li.

A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness

A preliminary double-blind controlled study on the prophylactic effect of carbamazepine on recurrent manic-depressive psychotics was conducted with 22 patients using an inert placebo in ten subjects as a control drug, and it is suggested that carbamazepsine is a useful drug for theProphylaxis of manic- Depressive illness.

Comparison of efficacy of lithium carbonate and chlorpromazine in mania. Report of collaborative study group on treatment of mania in Japan.

Onset of the therapeutic effect of lithium carbonate was within ten days of medication in 65% of patients, significantly faster than with chlorpromazine.

The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients.

Both drugs were effective in two thirds of the patients and appeared about equal in most outcome measures, except for a significantly higher dropout rate for patients with mood-incongruent psychotic features who were assigned to the lithium group.

Treatment of depression with clonazepam

It is thought that clonazepam might be useful as an antidepressant for patients in whom conventional antidepressant treatment are contraindicated.

Anti‐Manic and Prophylactic Effects of Carbamazepine (Tegretol) on Manic Depressive Psychosis A Preliminary Report

The prophylactic effect on MDP ofCAZP did not parallel that of lithium salt, but CAZP may be effective on cases which did not respond to lithium and vice versa.

A double‐blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders

The results suggest that carbamazepine, when used in combination with neuroleptics, is a useful drug for the treatment of excited states of patients with schizophrenic and schizoaffective disorders.

Carbamazepine in manic-depressive illness: a new treatment.

The authors evaluated carbamazepine (Tegretol), a drug of choice for treatment of temporal lobe epilepsy, in a double-blind placebo-controlled trial in patients with manic-depressive illness. Seven